Global Atherosclerosis Therapeutics Market Size By Type (Small Molecules, Biologics), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Atherosclerosis Therapeutics Market was valued at USD 53.7 billion in 2023 and is projected to reach USD 87.4 billion by 2031, growing at a CAGR of 6.3% during the forecast period (2023–2031). The market is driven by the rising prevalence of cardiovascular diseases, increasing geriatric population, and lifestyle-related risk factors such as obesity, smoking, and sedentary behavior. The growing emphasis on early diagnosis, innovative treatment pipelines, and favorable reimbursement policies is further fueling market expansion. As healthcare providers and governments push for better cardiovascular health outcomes, demand for atherosclerosis therapeutics is expected to surge.

Drivers:

1. Rising Prevalence of Cardiovascular Diseases:

Atherosclerosis is a leading contributor to heart attacks and strokes. With cardiovascular diseases remaining the primary cause of global mortality, the demand for effective therapeutics is growing rapidly.

2. Aging Global Population:

The risk of atherosclerosis increases with age. As the global elderly population continues to rise, especially in developed regions, the demand for chronic disease treatments including anti-atherosclerotic drugs is intensifying.

3. Technological Advancements in Drug Development:

Biotechnology and pharmaceutical companies are increasingly investing in advanced drug formulations, such as PCSK9 inhibitors and monoclonal antibodies, improving treatment efficacy and patient outcomes.

Restraints:

1. High Treatment Costs:

Advanced atherosclerosis therapies, especially biologics, can be expensive. This limits accessibility, particularly in low- and middle-income countries lacking robust reimbursement frameworks.

2. Side Effects and Drug Adherence Issues:

Certain medications used for atherosclerosis, such as statins, may have adverse effects, leading to poor adherence and reducing treatment effectiveness.

Opportunity:

1. Expansion in Emerging Markets:

Growing healthcare infrastructure and increasing awareness in Asia-Pacific, Latin America, and parts of Africa present strong opportunities for market penetration and therapeutic expansion.

2. Precision Medicine and Personalized Therapies:

Advancements in genomics and biomarker-based treatments are creating opportunities to develop customized therapies, enhancing outcomes and minimizing side effects.

Market by System Type Insights:

The market is segmented by drug class, with Statins holding the largest market share in 2023. Statins remain the cornerstone of atherosclerosis treatment due to their effectiveness in lowering LDL cholesterol. However, the PCSK9 Inhibitors segment is witnessing the fastest growth owing to their potent lipid-lowering capabilities and acceptance in high-risk patient populations.

Market by End-use Insights:

In terms of end-use, Hospitals & Clinics accounted for the highest market share in 2023. This is attributed to the high volume of patients, availability of specialized care, and advanced treatment options. Meanwhile, Homecare Settings are projected to experience strong growth due to the rise in telemedicine, remote monitoring tools, and patient-centric care models.

Market by Regional Insights:

North America dominated the global atherosclerosis therapeutics market in 2023, driven by robust healthcare infrastructure, high prevalence of lifestyle diseases, and rapid adoption of advanced therapeutics. Asia-Pacific is expected to register the highest CAGR through 2031, supported by growing healthcare expenditure, urbanization, and increased focus on preventive healthcare.

Competitive Scenario:

Key players in the global atherosclerosis therapeutics market include Pfizer Inc., Amgen Inc., AstraZeneca plc, Novartis AG, Merck & Co., Sanofi, GlaxoSmithKline plc, AbbVie Inc., Johnson & Johnson, and Bayer AG. These companies are focusing on expanding their drug pipelines, obtaining regulatory approvals, and entering strategic partnerships.

Key Market Developments:

In 2024, Amgen received FDA approval for an expanded indication of its PCSK9 inhibitor Repatha®, targeting broader high-risk patient segments.

In 2023, Novartis launched a clinical trial for a novel anti-inflammatory agent aimed at treating residual cardiovascular risk in atherosclerotic patients.

Pfizer partnered with a leading diagnostics firm in 2025 to develop biomarker-guided treatment protocols for early-stage atherosclerosis.

Scope of Work – Global Atherosclerosis Therapeutics Market

FAQs:

1) What is the current market size of the Global Atherosclerosis Therapeutics Market?

The market size was valued at USD 53.7 billion in 2023.

2) What is the major growth driver of the Global Atherosclerosis Therapeutics Market?

The rising prevalence of cardiovascular diseases and aging population are the key growth drivers.

3) Which is the largest region during the forecast period in the Global Atherosclerosis Therapeutics Market?

North America held the largest market share in 2023 and continues to dominate due to advanced healthcare systems.

4) Which segment accounted for the largest market share in the Global Atherosclerosis Therapeutics Market?

The Statins segment accounted for the largest share by drug class in 2023.

5) Who are the key market players in the Global Atherosclerosis Therapeutics Market?

Key players include Pfizer Inc., Amgen Inc., AstraZeneca, Novartis AG, Merck & Co., Sanofi, and others.